131 related articles for article (PubMed ID: 36050598)
21. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy.
Bjerre KP; Clemmensen TS; Berg K; Poulsen SH; Hvas AM; Grove EL; Løgstrup BB; Jakobsen L; Thim T; Kristensen SD; Eiskjær H
J Heart Lung Transplant; 2020 Apr; 39(4):371-378. PubMed ID: 32067865
[TBL] [Abstract][Full Text] [Related]
22. Comparison of mid-term clinical outcome in heart transplantation patients using mycophenolate mofetil vs. enteric-coated mycophenolate sodium.
Jeon K; Kim D; Choi JO; Cho YH; Sung K; Oh J; Cho HJ; Jung SH; Lee HY; Park JJ; Choi DJ; Kang SM; Kim JJ; Jeon ES
Front Cardiovasc Med; 2022; 9():957299. PubMed ID: 36082128
[TBL] [Abstract][Full Text] [Related]
23. The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.
Clerkin KJ; Restaino SW; Zorn E; Vasilescu ER; Marboe CC; Mancini DM
J Heart Lung Transplant; 2016 Sep; 35(9):1059-66. PubMed ID: 27423693
[TBL] [Abstract][Full Text] [Related]
24. Pretransplant malignancy as a risk factor for posttransplant malignancy after heart transplantation.
Yoosabai A; Mehta A; Kang W; Chaiwatcharayut W; Sampaio M; Huang E; Bunnapradist S
Transplantation; 2015 Feb; 99(2):345-50. PubMed ID: 25606783
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Solid Organ Transplant Recipients With Preexisting Malignancies in Remission: A Systematic Review and Meta-Analysis.
Acuna SA; Huang JW; Daly C; Shah PS; Kim SJ; Baxter NN
Transplantation; 2017 Mar; 101(3):471-481. PubMed ID: 27101077
[TBL] [Abstract][Full Text] [Related]
26. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis.
Perkel D; Czer LS; Morrissey RP; Ruzza A; Rafiei M; Awad M; Patel J; Kobashigawa JA
Transplant Proc; 2013; 45(6):2384-6. PubMed ID: 23953552
[TBL] [Abstract][Full Text] [Related]
27. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
[TBL] [Abstract][Full Text] [Related]
28. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
Coutance G; d'Orio V; Belin L; Bréchot N; Saheb S; Lebreton G; Bouglé A; Rouvier P; Gautreau C; Ouldammar S; Chamillard X; Huot M; Amour J; Combes A; Leprince P; Varnous S
Transplantation; 2019 Jul; 103(7):1439-1449. PubMed ID: 30376551
[TBL] [Abstract][Full Text] [Related]
29. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.
Delgado JF; Reyne AG; de Dios S; López-Medrano F; Jurado A; Juan RS; Ruiz-Cano MJ; Dolores Folgueira M; Gómez-Sánchez MÁ; Aguado JM; Lumbreras C
J Heart Lung Transplant; 2015 Aug; 34(8):1112-9. PubMed ID: 25940077
[TBL] [Abstract][Full Text] [Related]
30. Dual-organ transplantation in older recipients: outcomes after heart-kidney transplant versus isolated heart transplant in patients aged ≥65 years.
Reich H; Dimbil S; Levine R; Megna D; Mersola S; Patel J; Kittleson M; Czer L; Kobashigawa J; Esmailian F
Interact Cardiovasc Thorac Surg; 2019 Jan; 28(1):45-51. PubMed ID: 29982486
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of Heart Transplant Recipients With Preexisting Malignancies.
Wang YJ; Chiang TY; Hii IH; Ting M; Tsao CI; Cheng BC; Wang SS
Transplant Proc; 2018 Nov; 50(9):2738-2741. PubMed ID: 30401387
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of cardiac allograft vasculopathy: Importance of the International Society for Heart and Lung Transplantation angiographic grading scale.
Van Keer JM; Van Aelst LNL; Rega F; Droogne W; Voros G; Meyns B; Vanhaecke J; Emonds MP; Janssens S; Naesens M; Van Cleemput J
J Heart Lung Transplant; 2019 Nov; 38(11):1189-1196. PubMed ID: 31543298
[TBL] [Abstract][Full Text] [Related]
33. The clinical impact of donor-specific antibodies in heart transplantation.
Barten MJ; Schulz U; Beiras-Fernandez A; Berchtold-Herz M; Boeken U; Garbade J; Hirt S; Richter M; Ruhpawar A; Sandhaus T; Schmitto JD; Schönrath F; Schramm R; Schweiger M; Wilhelm M; Zuckermann A
Transplant Rev (Orlando); 2018 Oct; 32(4):207-217. PubMed ID: 29804793
[TBL] [Abstract][Full Text] [Related]
34. Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada.
Clarke B; Ducharme A; Giannetti N; Kim D; McDonald M; Pflugfelder P; Rajda M; Sénéchal M; Stadnick E; Toma M; Zieroth S; Isaac D
J Heart Lung Transplant; 2017 May; 36(5):491-498. PubMed ID: 28162932
[TBL] [Abstract][Full Text] [Related]
35. Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies.
Batra J; DeFilippis EM; Golob S; Clerkin K; Topkara VK; Habal MV; Restaino S; Griffin J; Hi Lee S; Latif F; Farr MA; Sayer G; Raikelkar J; Uriel N
Circ Heart Fail; 2022 Apr; 15(4):e008968. PubMed ID: 35094567
[TBL] [Abstract][Full Text] [Related]
36. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection.
Crescioli C; Buonamano A; Scolletta S; Sottili M; Francalanci M; Giomarelli P; Biagioli B; Lisi G; Pradella F; Serio M; Romagnani P; Maccherini M
Transplantation; 2009 Jan; 87(2):249-55. PubMed ID: 19155980
[TBL] [Abstract][Full Text] [Related]
37. The impact of mean first-year heart rate on outcomes after heart transplantation: does it make a difference?
Shah AB; Patel JK; Rafiei M; Morrissey RP; Kittleson MM; Kobashigawa JA
Clin Transplant; 2013; 27(5):659-65. PubMed ID: 23924048
[TBL] [Abstract][Full Text] [Related]
38. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
39. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression.
Groetzner J; Kaczmarek I; Mueller M; Huber S; Deutsch A; Daebritz S; Arbogast H; Meiser B; Reichart B
J Heart Lung Transplant; 2005 Nov; 24(11):1787-92. PubMed ID: 16297783
[TBL] [Abstract][Full Text] [Related]
40. Tumor Recurrence and Graft Survival in Renal Transplant Recipients with a History of Pretransplant Malignancy: A Matched Pair Analysis.
Becker F; Mehdorn AS; Getsopulos V; Schütte-Nütgen K; Reuter S; Suwelack B; Pascher A; Brockmann JG; Bahde R
J Clin Med; 2021 May; 10(11):. PubMed ID: 34071904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
